Chronic Daily Headache: A Rational Approach to a Challenging Problem

Jonathan Gladstone; Eric Eross; David Dodick

doi:10.1055/s-2003-814738

Seminars in Neurology, Table of Contents

Semin Neurol 2003; 23(3): 265-276
DOI: 10.1055/s-2003-814738

Chronic Daily Headache: A Rational Approach to a Challenging Problem

Jonathan Gladstone¹ , Eric Eross² , David Dodick³

¹Headache Fellow, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
²Associate Consultant, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
³Associate Professor, Department of Neurology, Mayo Clinic, Scottsdale, Arizona

Abstract

ABSTRACT

Chronic daily headache (CDH) is a significant public health problem with 3 to 5% of the population worldwide experiencing daily or near-daily headaches. Patients with CDH can be particularly challenging, and clinicians require a systematic approach to help guide investigations and management. The revised 2004 International Headache Society Classification Criteria introduces formalized criteria for several CDH disorders including chronic migraine and medication overuse headache as well as new daily persistent headache, hemicrania continua, hypnic headache, and SUNCT syndrome. Medication overuse is common in patients with CDH who present to physicians. Familiarity and comfort with drug-withdrawal and detoxification strategies is therefore essential. Patients with chronic migraine and chronic cluster experience significant disability and diminished quality of life. The ability to manage these patients effectively is a rewarding clinical experience.

KEYWORDS

Chronic daily headache - medication overuse headache - migraine - cluster headache

Full Text

References

REFERENCES

1 Scher A I, Stewart W F, Liberman J. et al . Prevalence of frequent headache in a population sample. Headache . 1998; 38 497-506
2 Castillo J, Munoz J, Guitera V. et al . Epidemiology of chronic daily headache in the general population. Headache . 1999; 39 190-196
3 Wang S J, Fuh J L, Lu S R. et al . Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. Neurology . 2000; 54 314-319
4 Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep . 2001; 5 529-536
5 Lanteri-Minet M, Auray J P, El Hasnaoui A. Prevalence and description of chronic daily headache in the general population of France. Pain . 2003; 102 143-149
6 Mathew N T. Chronic refractory headache. Neurology . 1993; 43 (suppl 3) S26-S33
7 D'Amico D, Usai S, Grazzi L. et al . Quality of life and disability in primary chronic daily headache. Neurol Sci . 2003; 24 S97-S100
8 Guitera V, Munoz P, Castillo J. et al . Quality of life in chronic daily headache. A study in general population. Neurology . 2002; 58 1062-1065
9 Wang S J, Fuh J L, Lu S R. et al . Quality of life differs among headache diagnoses: analysis of SF-35 survey in 901 headache patients. Pain . 2001; 89 285-292
10 Welch K M, Goadsby P J. Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol . 2002; 15 287-295
11 Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia . 2004; 24(suppl 1) 1-160
12 Mokri B. Headaches caused by decreased intracranial pressure: diagnosis and management. Curr Opin Neurol . 2003; 16 319-326
13 Dodick D W, Mosek A C, Campbell J K. The hypnic (“alarm clock”) headache syndrome. Cephalalgia . 1998; 18 152-156
14 Dodick D. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia . 2001; 21 869-872
15 Peres M F, Silberstein S D, Nahmias S. et al . Hemicrania continua is not that rare. Neurology . 2001; 57 948-951
16 Rozen T D. New daily persistent headache. Curr Pain Headache Rep . 2003; 7 218-223
17 Tepper S J. Analgesic overuse is a cause of chronic daily headache. Headache . 2002; 42 543-547
18 Dodick D W. Analgesic overuse is not a cause of chronic daily headache. Headache . 2002; 42 547-554
19 Dowson A J, Dodick D W, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis (in press). CNS Drugs 2003.
20 Silverman K, Evans S M, Strain E C. et al . Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med . 1992; 327 1109-1114
21 Bahra A, Walsh M, Menon S. et al . Does chronic daily headache arise de novo in association with regular use of analgesics?. Headache . 2003; 43 179-190
22 Young W B. Medication overuse headache. Curr Treat Options Neurol . 2001; 3 181-188
23 Zed P J, Loewen P S, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother . 1999; 33 61-72
24 Boes C, Jones J M, Dodick S W. Self-administered subcutaneous dihydroergotamine in the outpatient treatment of chronic daily headache with medication overuse. Headache . 2000; 40 402
25 Mathew N T, Stubits E, Nigam M P. Transformation of episodic migraine into daily headache: analysis of factors. Headache . 1982; 22 66-68
26 Silberstein S D, Lipton R B, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised HIS criteria. Neurology . 1996; 47 871-875
27 Matthew N T. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin . 1997; 15 167-186
28 Scher A., Lipton R B, Stewart W F. Risk factors for chronic daily headache. Curr Pain Headache Rep . 2002; 6 486-491
29 Scher A I, Lipton R B, Stewart W F. Habitual snoring as a risk factor for chronic daily headache. Neurology . 2003; 60 1366-1368
30 Bahra A, Matharu M S, Buchel C, Frackowiak R S, Goadsby P J. Brainstem activation specific to migraine headache. Lancet . 2001; 357 1016-1017
31 Tracey I, Ploghaus A, Gati J S. et al . Imaging attentional modulation of pain in the periaqueductal gray in humans. J Neurosci . 2002; 22 2748-2752
32 Silberstein S D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology . 2000; 55 754-762
33 Brandes J L, Jacobs D, Neto W. et al . Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, parallel study (MIGR-002). Neurology . 2003; 60 A238
34 Mathew N T, Schmitt J, Jacobs D. et al . Topiramate in migraine prevention (MIGR-001): effect on migraine frequency. Neurology . 2003; 60 A336
35 Ondo W G, Vuong K D, Derman H S. Botulinum toxin A (BOTOX^®) for chronic daily headache: a randomized placebo-controlled, parallel design study (in press). Cephalalgia 2003.
36 Freitag F G, Collins S D, Carlson H A. et al . Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology . 2002; 58 1652-1659
37 Storer R J, Goadsby P J. Topiramate inhibits trigeminovascular traffic in the cat: possible locus of action in the prevention of migraine. Neurology . 2003; 60(S1) A238-A239
38 Cui M, Aoki K R. Botulinum toxin type A (BONT/A) reduces inflammatory pain in the rat formalin model. Cephalalgia . 2000; 20 414
39 Cui M, Li S, You S, Khanijou S, Aoki K R. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing. International Conference 2002 Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hanover, Germany, June 8-11, 2002. Naunyn Schmiedebergs Arch Pharmacol . 2002; 365 (suppl 2) R17
40 Rosales R L, Arimura K, Ikenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve . 1996; 19 488-496
41 Silberstein S D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother . 2001; 2 1649-1654
42 Dodick D W, Capobianco D J. Treatment and management of cluster headache. Curr Pain Headache Rep . 2001; 5 83-91
43 Dodick D, Rozen T, Goadsby P, Silberstein S. Cluster headache. Cephalalgia . 2000; 20 787-803
44 May A, Leone M. Update on cluster headache. Curr Opin Neurol . 2003; 16 333-340
45 Leone M, Franzini A, D'Amico A. et al . Preliminary results and follow up of stereotactic electrode implant in posterior hypothalamic gray matter to relieve intractable chronic cluster headache. Neurology . 2002; 58 89-90